StockClub

RXRX

RXRXRecursion Pharmaceuticals, Inc.$ --
Recursion Pharmaceuticals, Inc.

Recursion Pharmaceuticals, Inc.

RXRX

$ -

-

Review earnings summary, surprise history, and upcoming forecasts.

wallet
Earnings Summary
Updated: 03/31/2026FY2026 Q1
Revenue
6M USD
YoY -56.1%
Operating Income
-129M USD
YoY +32.8%
Net Income
-118M USD
YoY +42.0%
EPS
-0.22$
YoY +56.0%

Revenue

$6.5M
FY2024 Q2$27.9M
$27.9M
Q2
FY2024 Q3$54M
$54M
Q3
FY2024 Q4$58.5M
$58.5M
Q4
FY2025 Q1$14.7M
$14.7M
Q1
FY2025 Q2$33.8M
$33.8M
Q2
FY2025 Q3$39M
$39M
Q3
FY2025 Q4$74.6M
$74.6M
Q4
FY2026 Q1$6.5M
$6.5M
Q1
Actual
$-8.3M (-56.1%)

Net Income

$-117.5M
FY2024 Q2$-188.9M
$-188.9M
Q2
FY2024 Q3$-284.6M
$-284.6M
Q3
FY2024 Q4$-463.5M
$-463.5M
Q4
FY2025 Q1$-202.5M
$-202.5M
Q1
FY2025 Q2$-374.4M
$-374.4M
Q2
FY2025 Q3$-536.6M
$-536.6M
Q3
FY2025 Q4$-644.8M
$-644.8M
Q4
FY2026 Q1$-117.5M
$-117.5M
Q1
Actual
+$85M (+42.0%)

Surprise History

Actual RevenueAnalyst Estimate
FY2020
Actual:$3.4M
FY2020
$3.4M
FY2021MISS
Actual:$10M
Est:$12.3M
FY2021MISS
$10M
FY2022MISS
Actual:$39.7M
Est:$48.3M
FY2022MISS
$39.7M
FY2023MISS
Actual:$43.9M
Est:$49.6M
FY2023MISS
$43.9M
FY2024MISS
Actual:$58.8M
Est:$70.7M
FY2024MISS
$58.8M
FY2025BEAT
Actual:$74.7M
Est:$61.5M
FY2025BEAT
$74.7M

Analyst Estimates